Liraglutide narrows the range of circadian glycemic variations in japanese type 2 diabetes patients and nearly flattens these variations in drug-naive type 2 diabetes patients: A continuous glucose monitoring-based study

Diabetes Technology and Therapeutics

Volumn 13, Issue 11, 2011, Pages 1139-1144

  Mori, Yutaka ^a,b   Taniguchi, Yukiko ^c   Sezaki, Kazunori ^d   Yokoyama, Junichi ^a   Utsunomiya, Kazunori ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kawachi gun   (Japan)

^c Department of Internal Medicine ^*  (Japan)

^d Shinyamanote Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLIMEPIRIDE; GLUCOSE; LIRAGLUTIDE; SULFONYLUREA;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DIET THERAPY; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLYCEMIC CONTROL; GLYCEMIC VARIATION; HOSPITAL PATIENT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; JAPANESE; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; ORAL GLUCOSE TOLERANCE TEST; PILOT STUDY; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE SELF-MONITORING; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PILOT PROJECTS; SULFONYLUREA COMPOUNDS; YOUNG ADULT;

EID: 80055042576     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2011.0137     Document Type: Article

References (12)

1. Seino Y, Rasmussen MF, Nishida T, Kaku K: Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin 2010;26:1013-1022.
2. Kaku K, Rasmussen MF, Clauson P, Seino Y: Improved glycemic control with minimal hypoglycemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab 2010; 12:341-347.
3. Flint A, Kapitza C, Hindsberger C, Zdravkovic M: The oncedaily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv Ther 2011;28:216-226.
4. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF: Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970;19: 644-655.
5. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycemia by exogeneous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-744. (Pubitemid 23218642)
6. Nagashima K, Inagaki N: Progress in therapy for diabetes mellitus-insulin-secretion inducing oral hypoglycemic agents. J Jpn Soc Intern Med 2009;98:737-741.
7. Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, An B, Galecki A, Halter JB: The GLP-1 derivative NN2211 restores b-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003;52:1786-1791. (Pubitemid 36792471)
8. Mori Y: Continuous glucose monitoring (CGM). J Ther 2010;92:569-576.
9. Mori Y, Shiozaki M, Matsuura K, Tanaka T, Yokoyama J, Utsunomiya K: Evaluation of efficacy of acarbose on glucose fluctuation and postprandial glucose using continuous glucose monitoring in type 2 diabetes mellitus. Diabetes Technol Ther 2011;13:467-470.
10. Mori Y, Taniguchi Y, Matuura K, Sezaki K, Yokoyama J, Utsunomiya K: Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring. Diabetes Technol Ther 2011;13:699-703.
11. Zhou J, Li H, Ran X, Yang W, Li Q, Peng Y, Li Y, Gao X, Wang W, Jia W: Reference values for continuous glucose monitoring in Chinese subjects. Diabetes Care 2009;32:1188-1193.
12. Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Garber A, Thomsen AB, Hartvig H, Davies M: One year of liraglutide treatment offers sustained and more effective glycaemiccontrol and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomized, parallel-group, open-label trial. Int J Clin Pract 2011;65:397-407.